Jeremy Grantham Enanta Pharmaceuticals Inc Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$41.16 - $47.47 $2.07 Million - $2.39 Million	-50,300 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$43.36 - $53.53 $1.6 Million - $1.97 Million	-36,800 Reduced 42.25%	50,300 $2.3 Million
Q2 2020 Aug 13, 2020	BUY	$46.37 - $57.58 $268,946 - $333,964	5,800 Added 7.13%	87,100 $4.37 Million
Q1 2020 May 14, 2020	BUY	$40.22 - $62.0 $3.27 Million - $5.04 Million	81,300 New	81,300 $4.18 Million
Q2 2018 Aug 14, 2018	SELL	$81.85 - $120.51 $548,395 - $807,417	-6,700 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$57.91 - $92.15 $324,296 - $516,040	-5,600 Reduced 45.53%	6,700 $542,000
Q4 2017 Feb 14, 2018	BUY	$45.65 - $59.37 $561,495 - $730,251	12,300	12,300 $722,000

107

19.1M

9.7K

12.4K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $148M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.